http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
-
Merck and Gilead discontinue lung cancer drug combination trial
-
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
-
MilliporeSigma Appoints New Heads of Discovery Solutions and Strategy & Business Development
-
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
-
FDA grants breakthrough therapy designation to Merck's KRAS G12C inhibitor
-
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
-
Merck to Participate in the Jefferies Global Healthcare Conference
-
Merck Announces Third-Quarter 2026 Dividend
-
Merck receives EU committee approval recommendation for bladder cancer drug combo
-
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasiv
-
Merck endometrial cancer drug meets survival goals in phase 3 trial
-
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or R
-
Merck to present oncology data across 25 cancer types at ASCO 2026
-
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
-
Merck publishes synthesis method for oral PCSK9 inhibitor in Science
-
Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
-
MilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
-
Merck Animal Health Selects Salesforce’s Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees
-
Merck completes $5.8 billion acquisition of Terns Pharmaceuticals
-
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
-
Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of
-
Merck clears HSR waiting period for $53 per share Terns acquisition
-
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
-
Merck and Google Cloud announce $1 billion AI partnership
-
Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
-
FDA approves Merck's IDVYNSO for HIV-1 treatment switch
-
FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)
-
Merck and Eisai report failed kidney cancer drug trial results
-
MilliporeSigma Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography
-
Merck and Eisai trial for kidney cancer combination therapy fails endpoints
-
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
-
FDA grants priority review for Merck's KEYTRUDA combinations in bladder cancer
-
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Pat
-
European Commission approves Merck's ENFLONSIA for RSV prevention in infants
-
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
-
FDA grants priority review to ifinatamab deruxtecan for lung cancer treatment
-
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Bas
-
Merck launches tender offer to acquire Terns Pharmaceuticals for $53 per share
-
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
-
Merck starts phase 2b/3 trial for eye disease drug MK-8748
-
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular
-
European Commission approves KEYTRUDA plus paclitaxel for ovarian cancer
-
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Receive
-
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
-
Merck drug shows superior cholesterol reduction in phase 3 trial
-
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies
-
Merck's WINREVAIR shows promise in heart failure trial
-
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension
-
Merck to acquire Terns Pharmaceuticals for $6.7 billion
